subsequently been applied across a range of diseases and disciplines to substantial benefit, provoking the notion of mechanistically common immune-mediated diseases. Second, the application of sound strategic principles in the use of such agents is increasingly driving improvements in outcome. Herein I discuss some of the pathogenesis discovery approaches that we have employed to unravel those mechanisms that drive chronicity and co-morbidity. Such studies have evolved to support a move to defining molecular taxonomies of common inflammatory diseases, seeking in turn to develop clinically useful endotypes that can confer enriched clinical responses with reduced risk to patients. Finally, I will explore parallel translational studies in which the same principles have been applied to other common rheumatic conditions with surprising results. Disclosure statement: I.C. has received consulting fees for discussions with AbbVie, Bristol-Myers Squibb, Pfizer, Novartis, AstraZeneca, Janssen and UCB and has received research support for the University of Glasgow from Bristol-Myers Squibb, UCB, AstraZeneca, Medimmune and Janssen.
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